Abstract
Advances in the characterization of pain signaling in recent years indicate that distinct neurophysiological and neurochemical mechanisms contribute to pain arising from injury to the nervous system (neuropathic pain). Tissue injury results in the release of pro-nociceptive mediators that sensitize peripheral nerve terminals (peripheral sensitization), leading to neurochemical and phenotypic alterations of sensory neurons and increased excitability of spinal cord dorsal horn neurons (central sensitization). In addition, the response of the nervous system to pain is not static, but is modulated by descending systems originating in the brain that can modulate pain thresholds. In this review, attention is given to the experimental modeling of neuropathic pain in preclinical studies. Recently, an increased understanding of the neurophysiological plasticity of the nervous system in response to chronic pain has led to the discovery and development of novel pharmacological interventions that may have clinical utility in treating neuropathic pain.
Keywords: Neuropathic pain, spinal nerve ligation, chronic constriction injury, diabetic neuropathy, chemotherapy-induced neuropathy
Current Pharmaceutical Design
Title: Neuropathic Pain: Models and Mechanisms
Volume: 15 Issue: 15
Author(s): Janel M. Boyce-Rustay and Michael F. Jarvis
Affiliation:
Keywords: Neuropathic pain, spinal nerve ligation, chronic constriction injury, diabetic neuropathy, chemotherapy-induced neuropathy
Abstract: Advances in the characterization of pain signaling in recent years indicate that distinct neurophysiological and neurochemical mechanisms contribute to pain arising from injury to the nervous system (neuropathic pain). Tissue injury results in the release of pro-nociceptive mediators that sensitize peripheral nerve terminals (peripheral sensitization), leading to neurochemical and phenotypic alterations of sensory neurons and increased excitability of spinal cord dorsal horn neurons (central sensitization). In addition, the response of the nervous system to pain is not static, but is modulated by descending systems originating in the brain that can modulate pain thresholds. In this review, attention is given to the experimental modeling of neuropathic pain in preclinical studies. Recently, an increased understanding of the neurophysiological plasticity of the nervous system in response to chronic pain has led to the discovery and development of novel pharmacological interventions that may have clinical utility in treating neuropathic pain.
Export Options
About this article
Cite this article as:
Boyce-Rustay M. Janel and Jarvis F. Michael, Neuropathic Pain: Models and Mechanisms, Current Pharmaceutical Design 2009; 15 (15) . https://dx.doi.org/10.2174/138161209788186272
DOI https://dx.doi.org/10.2174/138161209788186272 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Releasing of Herpes Simplex Virus Carrying NGF in Subarachnoid Space Promotes the Functional Repair in Spinal Cord Injured Rats
Current Gene Therapy Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Manipulating Kynurenic Acid Levels in the Brain – On the Edge Between Neuroprotection and Cognitive Dysfunction
Current Topics in Medicinal Chemistry Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
Current Neuropharmacology Regulatory Strategies for Cell Death in Neurological Diseases
CNS & Neurological Disorders - Drug Targets Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology 5-Lipoxygenase and Cyclooxygenase Inhibitory Dammarane Triterpenoid 1 from Borassus flabellifer Seed Coat Inhibits Tumor Necrosis Factor-α Secretion in LPSInduced THP-1 Human Monocytes and Induces Apoptosis in MIA PaCa-2 Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Peptide modules for overcoming barriers of nucleic acids transport to cells
Current Topics in Medicinal Chemistry Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics?
CNS & Neurological Disorders - Drug Targets Synthesis and Preliminary Biochemical Evaluation of Novel Derivatives of PCP
Letters in Drug Design & Discovery The Relationship of Developmental Changes in White Matter to the Onset of Psychosis
Current Pharmaceutical Design Emerging Role of NF-κB in the Pathogenesis of Hepatic Encephalopathy
Current Signal Transduction Therapy Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Synthetic Inhibitors of Group IVA and Group VIA Phospholipase A2
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Capsaicin Paradox: Pain Relief by an Algesic Agent
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neurotoxicity and Side-Effects of Highly Active Antiretroviral Therapy [HAART] on the Central and Peripheral Nerve System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Metastasis-Inducing S100A4 Protein: Implication in Non-Malignant Human Pathologies
Current Molecular Medicine